M&A / Deals AZ forges ever-closer ties with China’s CSPC Pharma PharmaphorumAstraZeneca has returned to China's CSPC Pharma to fill its R D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.Read full story pharminent July 2, 2026 (Last updated: July 3, 2026) Pharmaphorum AstraZeneca has returned to China’s CSPC Pharma to fill its R D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche’s KRAS drug tops its rivals in lung cancer trialNext: Novartis receives European Commission approval for Itvisma for spinal muscular atrophy Related Stories M&A / Deals Insilico Medicine, Takeda partner on AI-driven drug discovery pharminent July 2, 2026 M&A / Deals Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal pharminent July 1, 2026 M&A / Deals Zymeworks cuts deal to buy Theravance for $929m in cash pharminent June 29, 2026
